nach oben

Erschienen in:

19.03.2019 | Original Article

Understanding the gut–kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition

verfasst von: Sibei Tao, Lingzhi Li, Ling Li, Yuan Liu, Qian Ren, Min Shi, Jing Liu, Jing Jiang, Huichao Ma, Zhuo Huang, Zijing Xia, Jing Pan, Tiantian Wei, Yan Wang, Peiyun Li, Tian Lan, Xi Tang, Xiaoxi Zeng, Song Lei, Huairong Tang, Liang Ma, Ping Fu

Erschienen in: Acta Diabetologica | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims

Type 2 diabetes mellitus (T₂DM) has a rising prevalence and gut microbiota involvement is increasingly recognized. Diabetic nephropathy (DN) is a major complication of T₂DM. The aim of the study was to understand the gut–kidney axis by an analysis of gut microbiota composition among biopsy-proven DN, T₂DM without kidney disease, and healthy control.

Methods

Fecal samples were collected from 14 DNs, 14 age/gender-matched T₂DMs without renal diseases (DM), 14 age and gender-matched healthy controls (HC) and household contacts (HH) of DM group. The microbiota composition was analyzed by 16sRNA microbial profiling approach.

Results

Substantial differences were found in the richness of gut microbiota and the variation of bacteria population in DM compared to HC, and DN compared to DM, respectively. DM could be accurately distinguished from age/gender-matched healthy controls by the variable of genus g_Prevotella_9 (AUC = 0.9), and DN patients could be accurately distinguished from age/gender-matched DM by the variables of two genera (g_Escherichia-Shigella and g_Prevotella_9, AUC = 0.86). The microbiota composition of HH group was close to that of HC group, and was different from DM group. Under the same diet, DM could be more accurately detected by the same genus (g_Prevotella_9, AUC = 0.92).

Conclusion

Gut microbiota composition was explored to be related to the occurrence of biopsy-proven DN from DM. DM could be distinguished from HC by detecting g_Prevotella_9 level in feces, while DN was different from DM by the variables of g_Escherichia-Shigella and g_Prevotella_9, which potentially contributed to the physiopathological diagnosis of DN from DM.

Nur mit Berechtigung zugänglich

Demmer RT, Zuk AM, Rosenbaum M, Desvarieux M (2013) Prevalence of diagnosed and undiagnosed type 2 diabetes mellitus among US adolescents: results from the continuous NHANES, 1999–2010. Am J Epidemiol 178(7):1106–1113PubMedPubMedCentral

Ma RC, Lin X, Jia W (2014) Causes of type 2 diabetes in China. Lancet Diabetes Endocrinol 2(12):980–991PubMed

Pitts-Tucker T (2012) Asian and Afro-Caribbean Britons have double the risk of type 2 diabetes. Br Med J 345:e6135

Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C (2013) Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159(8):543–551PubMed

Karlsson FH, Tremaroli V, Nookaew I et al (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498(7452):99–103PubMed

Qin J, Li Y, Cai Z et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490(7418):55–60PubMed

Zhang X, Shen D, Fang Z et al (2013) Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 8(8):e71108PubMedPubMedCentral

de Vos WM, Nieuwdorp M (2013) Genomics. A gut prediction. Nature 498(7452):48–49PubMed

Lau E, Carvalho D, Pina-Vaz C, Barbosa JA, Freitas P (2015) Beyond gut microbiota: understanding obesity and type 2 diabetes. Hormones 14(3):358–369PubMed

10.

Barsoum RS (2006) Chronic kidney disease in the developing world. N Engl J Med 354(10):997–999PubMed

11.

Du P, Fan B, Han H et al (2013) NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resistance in diabetic nephropathy. Kidney Int 84(2):265–276PubMed

12.

Zhang L, Long J, Jiang W et al (2016) Trends in chronic kidney disease in China. N Engl J Med 375(9):905–906PubMed

13.

de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305(24):2532–2539PubMedPubMedCentral

14.

Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24(2):302–308PubMedPubMedCentral

15.

Fineberg D, Jandeleit-Dahm KA, Cooper ME (2013) Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol 9(12):713–723PubMed

16.

Li L, Ma L, Fu P (2017) Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Dev Ther 11:3531–3542

17.

Ramezani A, Raj DS (2014) The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 25(4):657–670PubMed

18.

Cai L, Wu H, Li D, Zhou K, Zou F (2015) Type 2 diabetes biomarkers of human gut microbiota selected via iterative sure independent screening method. PLoS One 10(10):e0140827PubMedPubMedCentral

19.

Guo Z, Zhang J, Wang Z et al (2016) Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep 6:20602PubMedPubMedCentral

20.

Vaziri ND, Wong J, Pahl M et al (2013) Chronic kidney disease alters intestinal microbial flora. Kidney Int 83(2):308–315PubMed

21.

Levey AS, de Jong PE, Coresh J et al (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80(1):17–28PubMed

22.

Bakris GL, Agarwal R, Chan JC et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884–894PubMed

23.

Brenner D, Hiergeist A, Adis C et al (2018) The fecal microbiome of ALS patients. Neurobiol Aging 61:132–137PubMed

24.

Hiergeist A, Reischl U, Gessner A (2016) Multicenter quality assessment of 16S ribosomal DNA-sequencing for microbiome analyses reveals high inter-center variability. Int J Med Microbiol 306(5):334–342PubMed

25.

Mcardle BH, Anderson MJ (2011) Fitting multivariate models to community data: a comment on distance-based redundancy analysis. Ecology 82(1):290–297

26.

Zapala MA, Schork NJ (2006) Multivariate regression analysis of distance matrices for testing associations between gene expression patterns and related variables. Proc Natl Acad Sci USA 103(51):19430–19435PubMedPubMedCentral

27.

Chow J, Tang H, Mazmanian SK (2011) Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol 23(4):473–480PubMedPubMedCentral

28.

Hooper LV, Littman DR, Macpherson AJ (2012) Interactions between the microbiota and the immune system. Science 336(6086):1268–1273PubMedPubMedCentral

29.

Sekirov I, Russell SL, Antunes LC, Finlay BB (2010) Gut microbiota in health and disease. Physiol Rev 90(3):859–904PubMed

30.

Forslund K, Hildebrand F, Nielsen T et al (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528(7581):262–266PubMedPubMedCentral

31.

De Angelis M, Montemurno E, Piccolo M et al (2014) Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 9(6):e99006PubMedPubMedCentral

32.

Jiang S, Xie S, Lv D et al (2017) Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep 7(1):2870PubMedPubMedCentral

33.

Poesen R, Windey K, Neven E et al (2016) The influence of CKD on colonic microbial metabolism. J Am Soc Nephrol 27(5):1389–1399PubMed

34.

Nicholson JK, Holmes E, Kinross J et al (2012) Host–gut microbiota metabolic interactions. Science 336(6086):1262–1267PubMed

35.

Chen T, Zhang X, Long Y et al (2012) The association of plasma free amino acids with liver enzymes in Type 2 diabetic patients. J Endocrinol Investig 35(8):772–775

36.

Li M, Wang X, Aa J et al (2013) GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am J Physiol Renal Physiol 304(11):F1317–F1324PubMed

37.

Nakamura H, Jinzu H, Nagao K et al (2014) Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients. Nutr Diabetes 4:e133PubMedPubMedCentral

38.

Scanlan PD, Shanahan F, Clune Y et al (2008) Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol 10(3):789–798PubMed

39.

Vitali B, Ndagijimana M, Cruciani F et al (2010) Impact of a synbiotic food on the gut microbial ecology and metabolic profiles. BMC Microbiol 10:4PubMedPubMedCentral

40.

Sun L, Ma L, Ma Y, Zhang F, Zhao C, Nie Y (2018) Insights into the role of gut microbiota in obesity: pathogenesis, mechanisms, and therapeutic perspectives. Protein Cell 9(5):397–403PubMedPubMedCentral

41.

Andrade-Oliveira V, Amano MT, Correa-Costa M et al (2015) Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26(8):1877–1888PubMedPubMedCentral

42.

Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND (2014) Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 39(3):230–237PubMed

43.

Furusawa Y, Obata Y, Fukuda S et al (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504(7480):446–450PubMed

44.

Finegold SM, Dowd SE, Gontcharova V et al (2010) Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 16(4):444–453PubMed

45.

Rizzatti G, Lopetuso LR, Gibiino G et al (2017) Proteobacteria: a common factor in human diseases. Biomed Res Int 2017(9):1–7

46.

Wassenaar TM, Zimmermann K (2018) Lipopolysaccharides in food, food supplements, and probiotics: should we be worried? Eur J Microbiol Immunol 8(3):63–69

47.

Carrero JJ, Stenvinkel P (2009) Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 4(Suppl 1):S49–S55PubMed

48.

Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB (2013) Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 26(4):822–880PubMedPubMedCentral

49.

Clark DP (1989) The fermentation pathways of Escherichia coli. FEMS Microbiol Rev 63(3):223–234

50.

Liu J (2014) Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver. World J Gastroenterol 20(40):14672–14685PubMedPubMedCentral

51.

Mahmoodpoor F, Rahbar Saadat Y, Barzegari A, Ardalan M, Zununi Vahed S (2017) The impact of gut microbiota on kidney function and pathogenesis. Biomed Pharmacother 93:412–419PubMed

Titel: Understanding the gut–kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition
verfasst von: Sibei Tao
Lingzhi Li
Ling Li
Yuan Liu
Qian Ren
Min Shi
Jing Liu
Jing Jiang
Huichao Ma
Zhuo Huang
Zijing Xia
Jing Pan
Tiantian Wei
Yan Wang
Peiyun Li
Tian Lan
Xi Tang
Xiaoxi Zeng
Song Lei
Huairong Tang
Liang Ma
Ping Fu
Publikationsdatum: 19.03.2019
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 5/2019
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-019-01316-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Understanding the gut–kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition

Abstract

Aims

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Insulin pump settings and glucose patterns during a 1008-km non-stop bicycle race in a patient with type 1 diabetes mellitus

Glutamate interactions with obesity, insulin resistance, cognition and gut microbiota composition

Do microvascular changes occur preceding neural impairment in early-stage diabetic retinopathy? Evidence based on the optic nerve head using optical coherence tomography angiography

The STOP DIABETES study: when prevention works

Risk factor control and outpatient attendance in young adults with diabetes

Association of fasting glucose and glycated hemoglobin with the long-term risk of incident metabolic syndrome: Korean Genome and Epidemiology Study (KoGES)

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin